Showing 7961-7970 of 10601 results for "".
- Two L'Oreal Brands at Select Walgreenshttps://practicaldermatology.com/news/20120824-two_loreal_brands_at_select_walgreens/2459745/
- Cosmetic Surgery Forum Offering Early Bird Rateshttps://practicaldermatology.com/news/20120820-cosmetic_surgery_forum_offering_early_bird_rates/2459750/
- Healthcare Spending Growth Expected to Remain Lowhttps://practicaldermatology.com/news/20120603-healthcare_spending_growth_expected_to_remain_low/2459793/
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- Text Messaging Intervention Improves Cardiovascular Risk Behaviors in PsO Trialhttps://practicaldermatology.com/news/text-messaging-intervention-improves-cardiovascular-risk-behaviors-in-pso-trial/2487819/A structured text messaging intervention was shown to improve patient activation and several cardiovascular risk behaviors among adults with psoriasis, according to new findings published in JAMA Dermatology.
- LEO Pharma Reports Positive Phase 2 Pediatric Data for Tralokinumab in Atopic Dermatitishttps://practicaldermatology.com/news/leo-pharma-reports-positive-phase-2-pediatric-data-for-tralokinumab-in-atopic-dermatitis/2487767/LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://practicaldermatology.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Commentary Proposes Path to Cutting Plastic Waste in Dermatology Researchhttps://practicaldermatology.com/news/commentary-highlights-practical-route-to-cutting-plastic-waste-in-dermatology-research/2487685/The redesign of laboratory packaging to reduce plastic waste is a feasible near-term strategy for reducing plastic waste in skin-model research without disrupting validated experimental systems, according to a commentary in the Journal of Investigative Dermato
- FDA Expands ZORYVE Cream Approval to Children as Young as 2 Years With Plaque Psoriasishttps://practicaldermatology.com/news/fda-expands-zoryve-cream-approval-to-children-as-young-as-2-years-with-plaque-psoriasis/2487622/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) expanding the indication for ZORYVE (roflumilast) cream 0.3% to include the topical treatment of plaque psoriasis, including intertriginous areas, in children as young as 2 yea
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.